photoaging photoaging, Dihydromyricetin, facial rejuvenation
Conditions
Interventions
Participants will apply the serum to the entire face twice daily and use sunscreen throughout the study period.
Experimental Device
Dihydromyricetin Based Topical Serum
Sponsors
Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University
Eligibility
Sex/Gender
All
Age
30 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1. Male or female participants aged 30 to 45 years 2. Thai participants of Asian ethnicity with Fitzpatrick skin types III to V 3. Willingness to participate in the study and provide written informed consent 4. Moderate or greater facial photoaging as assessed by a dermatologist specializing in dermatologic surgery using the Glogau Classification of Photoaging
Exclusion criteria
Exclusion criteria: 1. Pregnant or breastfeeding women, determined by menstrual and contraceptive history. If pregnancy is suspected, a urine pregnancy test will be performed. Participants with a positive result or confirmed pregnancy will be excluded. 2. Participants with medical conditions affecting collagen synthesis or connective tissue integrity. 3. Participants with a known allergy or hypersensitivity to dihydromyricetin. 4. Use of oral or topical skin-whitening agents on the face within 3 months prior to study enrollment. 5. Use of oral antioxidant supplements, such as vitamin C, vitamin E, coenzyme Q10, or similar products. 6. Current smokers or participants with a history of excessive alcohol consumption. 7. History of facial skin-tightening procedures, including energy-based devices or thread lifting, within 6 months prior to study enrollment. 8. History of facial dermal filler injection within 6 months prior to study enrollment. 9. History of platelet-rich plasma (PRP) injection to the face within 6 months prior to study enrollment. 10. History of botulinum toxin injection to the face within 6 months prior to study enrollment. 11. History of collagen-stimulating laser procedures to the face, including picosecond laser, Er:YAG laser, Fractora, E-Matrix laser, or similar treatments, within 6 months prior to study enrollment. 12. Use of sex hormone therapy in any form (topical, oral, injectable, or implantable) within 6 months prior to study enrollment. 13. Participants with a diagnosed psychiatric disorder confirmed by a psychiatrist. 14. Participants who do not consent to facial photography for treatment assessment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Physician assessment baseline, 1, 2, 3, 4 , 5 and 6 months of using serum Quartile scale,Patients improvement baseline, 1, 2, 3, 4 , 5 and 6 months of using serum Quartile scale,Safety baseline, 1, 2, 3, 4 , 5 and 6 months of using serum adverse events | — |
Secondary
| Measure | Time frame |
|---|---|
| Volume change baseline, 1, 2, 3, 4 , 5 and 6 months of using serum QuantiffiCare,Skin pliability baseline, 1, 2, 3, 4 , 5 and 6 months of using serum Cutometer,Skin elasticity baseline, 1, 2, 3, 4 , 5 and 6 months of using serum Cutometer,Melanin index baseline, 1, 2, 3, 4 , 5 and 6 months of using serum Mexameter,Erythema index baseline, 1, 2, 3, 4 , 5 and 6 months of using serum Mexameter,Skin hydration baseline, 1, 2, 3, 4 , 5 and 6 months of using serum Corneometer,individual typology angle baseline, 1, 2, 3, 4 , 5 and 6 months of using serum Colorimeter,Sebum level baseline, 1, 2, 3, 4 , 5 and 6 months of using serum Sebumeter,Skin quality baseline, 1, 2, 3, 4 , 5 and 6 months of using serum Antera,Brown spots baseline, 1, 2, 3, 4 , 5 and 6 months of using serum VISIA,Red area baseline, 1, 2, 3, 4 , 5 and 6 months of using serum VISIA,UV spots baseline, 1, 2, 3, 4 , 5 and 6 months of using serum VISIA | — |
Countries
Thailand
Contacts
Public ContactRungsima Wanitphakdeedecha
Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University
Outcome results
None listed